Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy: A Glimmer of Hope?-Reference-Cited by-同舟云学术

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy: A Glimmer of Hope?

Published:2017-02-20 Issue:6 Volume:35 Page:692-693
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Van Der Steen Nele¹,Rolfo Christian Diego¹,Pauwels Patrick¹,Peters Godefridus J.¹,Giovannetti Elisa¹

Affiliation:

1. Nele Van Der Steen, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium; and VU Medical Center, Amsterdam, the Netherlands; Christian Diego Rolfo and Patrick Pauwels, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium; Godefridus J. Peters, VU Medical Center, Amsterdam, the Netherlands; and Elisa Giovannetti, VU Medical Center, Amsterdam, The Netherlands; and University of Pisa, Pisa, Italy

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.70.1987

Reference10 articles.

1. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

2. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

3. Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells

4. Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells

5. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al;Journal of Clinical Oncology;2017-02-20